DNTH Stock Analysis: Buy, Sell, or Hold?
DNTH - Dianthus Therapeutics, Inc. Common Stock
$85.34
-0.40 (-0.47%)
▼
5d:
-0.15%
30d:
-10.88%
90d:
+79.74%
BUY
HIGH Confidence
Analysis Updated: May 14, 2026 12:00 AM ET
Earnings: May 11, 2026
0d
Smart Money Accumulation
DNTH is down 8.5% this week, but smart money is accumulating calls. Top strike: $100 2026-06-18 with 5 OI. Call ratio: 100% View Scanner →
Strength: 9.3/10
Get Alerted When DNTH Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: DNTH shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
✅ BUY SIGNAL: DNTH shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
In-depth Analysis How we analyze
Valuation Analysis: DNTH is currently trading at $85.34, which is considered oversold relative to its 30-day fair value range of $85.63 to $91.90.
Technical Outlook: Technically, DNTH is in a strong uptrend. The price is currently testing key support at $83.12. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $125.83 (+47.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, DNTH is in a strong uptrend. The price is currently testing key support at $83.12. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $125.83 (+47.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$85.63 -
$91.90
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
86.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 47.4% below Wall St target ($125.83)
Trading Range Analysis
30-Day Trading Range
$85.63 -
$91.90
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$8.46
(9.9%)
Support & Resistance Levels
Support Level
$83.12
Resistance Level
$91.81
Current Trend
Strong Uptrend
Technical data as of
May 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-17.99
Wall Street Target
$125.83
(+47.4%)
Revenue Growth (YoY)
-60.2%
Share & Embed Analysis
Last updated: May 14, 2026 9:59 PM ET
Data refreshes hourly during market hours. Next update: 10:59 PM
Data refreshes hourly during market hours. Next update: 10:59 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DNTH showing a specific setup today?
Insider Activity (6 Months)
0
Buys
6
Sells
Net
INSIDERS SELLING
Recent Transactions
Ryan Savitz
SELL
8224 shares
2026-04-09
Ryan Savitz
SELL
114367 shares
2026-03-31
Edward Carr
SELL
43682 shares
2026-03-12
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$109 | 65 BUY |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$26 | 57 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$102 | 54 HOLD |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$130 | 52 HOLD |
Advanced DNTH Option Strategies
Professional options setups generated by AI based on today's DNTH price and gamma walls.
